CXCL9 serves as a biomarker of rheumatoid arthritis activity, regulated by IFN-γ and proinflammatory cytokines, which exacerbate synovial inflammation and joint damage [87]. The gene discussed is IFNG; the disease is rheumatoid arthritis.